JP2020504715A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020504715A5 JP2020504715A5 JP2019530439A JP2019530439A JP2020504715A5 JP 2020504715 A5 JP2020504715 A5 JP 2020504715A5 JP 2019530439 A JP2019530439 A JP 2019530439A JP 2019530439 A JP2019530439 A JP 2019530439A JP 2020504715 A5 JP2020504715 A5 JP 2020504715A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- membered
- halo
- cycloalkyl
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 193
- 125000005843 halogen group Chemical group 0.000 claims description 116
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 76
- 125000000217 alkyl group Chemical group 0.000 claims description 68
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 50
- 229910052799 carbon Inorganic materials 0.000 claims description 46
- 125000003545 alkoxy group Chemical group 0.000 claims description 44
- 125000003118 aryl group Chemical group 0.000 claims description 39
- -1 cyano, hydroxyl Chemical group 0.000 claims description 38
- 125000005842 heteroatom Chemical group 0.000 claims description 38
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 36
- 125000001072 heteroaryl group Chemical group 0.000 claims description 32
- 229910052739 hydrogen Inorganic materials 0.000 claims description 32
- 229910052760 oxygen Inorganic materials 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 29
- 229910052717 sulfur Inorganic materials 0.000 claims description 27
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 20
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 20
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 19
- 125000004043 oxo group Chemical group O=* 0.000 claims description 18
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 16
- 208000019838 Blood disease Diseases 0.000 claims description 16
- 125000000304 alkynyl group Chemical group 0.000 claims description 16
- 208000014951 hematologic disease Diseases 0.000 claims description 16
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 16
- 230000005764 inhibitory process Effects 0.000 claims description 15
- 102100035042 Histone-lysine N-methyltransferase EHMT2 Human genes 0.000 claims description 13
- 101000877312 Homo sapiens Histone-lysine N-methyltransferase EHMT2 Proteins 0.000 claims description 13
- 201000005787 hematologic cancer Diseases 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 10
- 206010011703 Cyanosis Diseases 0.000 claims description 10
- 102100035043 Histone-lysine N-methyltransferase EHMT1 Human genes 0.000 claims description 10
- 101000877314 Homo sapiens Histone-lysine N-methyltransferase EHMT1 Proteins 0.000 claims description 10
- 206010025323 Lymphomas Diseases 0.000 claims description 10
- 108060004795 Methyltransferase Proteins 0.000 claims description 10
- 102000016397 Methyltransferase Human genes 0.000 claims description 10
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 10
- 208000032839 leukemia Diseases 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 7
- 108091000080 Phosphotransferase Proteins 0.000 claims description 6
- 102000020233 phosphotransferase Human genes 0.000 claims description 6
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 5
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 5
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 208000018020 Sickle cell-beta-thalassemia disease syndrome Diseases 0.000 claims description 5
- 206010043391 Thalassaemia beta Diseases 0.000 claims description 5
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 5
- 201000003444 follicular lymphoma Diseases 0.000 claims description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 208000007056 sickle cell anemia Diseases 0.000 claims description 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 125000002619 bicyclic group Chemical group 0.000 claims description 4
- 125000006580 bicyclic heterocycloalkyl group Chemical group 0.000 claims description 4
- 150000001721 carbon Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000006574 non-aromatic ring group Chemical group 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 4
- 230000002489 hematologic effect Effects 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 claims description 2
- 108010055196 EphA2 Receptor Proteins 0.000 claims description 2
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims description 2
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims description 2
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims description 2
- 101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 claims description 2
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 claims description 2
- 101001059443 Homo sapiens Serine/threonine-protein kinase MARK1 Proteins 0.000 claims description 2
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 claims description 2
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 claims description 2
- 101150028321 Lck gene Proteins 0.000 claims description 2
- 101710138999 MAP kinase-interacting serine/threonine-protein kinase 2 Proteins 0.000 claims description 2
- 102100033610 MAP kinase-interacting serine/threonine-protein kinase 2 Human genes 0.000 claims description 2
- 102000001253 Protein Kinase Human genes 0.000 claims description 2
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 claims description 2
- 102100028921 Serine/threonine-protein kinase MARK1 Human genes 0.000 claims description 2
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 108060006633 protein kinase Proteins 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 5
- 238000000034 method Methods 0.000 description 11
- 125000004450 alkenylene group Chemical group 0.000 description 4
- 229940124639 Selective inhibitor Drugs 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022080211A JP2022110080A (ja) | 2016-12-19 | 2022-05-16 | Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物およびその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662436139P | 2016-12-19 | 2016-12-19 | |
| US62/436,139 | 2016-12-19 | ||
| US201762517840P | 2017-06-09 | 2017-06-09 | |
| US62/517,840 | 2017-06-09 | ||
| PCT/US2017/067192 WO2018118842A1 (en) | 2016-12-19 | 2017-12-19 | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022080211A Division JP2022110080A (ja) | 2016-12-19 | 2022-05-16 | Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020504715A JP2020504715A (ja) | 2020-02-13 |
| JP2020504715A5 true JP2020504715A5 (enExample) | 2021-02-04 |
Family
ID=60972416
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019530439A Pending JP2020504715A (ja) | 2016-12-19 | 2017-12-19 | Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物およびその使用方法 |
| JP2022080211A Pending JP2022110080A (ja) | 2016-12-19 | 2022-05-16 | Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022080211A Pending JP2022110080A (ja) | 2016-12-19 | 2022-05-16 | Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物およびその使用方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20200039998A1 (enExample) |
| EP (2) | EP4285906A3 (enExample) |
| JP (2) | JP2020504715A (enExample) |
| KR (1) | KR102693367B1 (enExample) |
| CN (2) | CN116041346A (enExample) |
| AU (3) | AU2017382830A1 (enExample) |
| BR (1) | BR112019012140A2 (enExample) |
| CA (1) | CA3045032A1 (enExample) |
| CL (2) | CL2019001664A1 (enExample) |
| CO (1) | CO2019006787A2 (enExample) |
| DK (1) | DK3555070T3 (enExample) |
| ES (1) | ES2955132T3 (enExample) |
| FI (1) | FI3555070T3 (enExample) |
| HU (1) | HUE063405T2 (enExample) |
| IL (1) | IL267090A (enExample) |
| LT (1) | LT3555070T (enExample) |
| MA (1) | MA47233A (enExample) |
| MX (1) | MX2019007234A (enExample) |
| PL (1) | PL3555070T3 (enExample) |
| PT (1) | PT3555070T (enExample) |
| SG (1) | SG10201913464TA (enExample) |
| SI (1) | SI3555070T1 (enExample) |
| TW (2) | TWI808067B (enExample) |
| WO (1) | WO2018118842A1 (enExample) |
| ZA (1) | ZA201904234B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016057931A1 (en) | 2014-10-10 | 2016-04-14 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
| EP4105203A1 (en) * | 2016-09-30 | 2022-12-21 | Epizyme Inc | Spiro-condensed indole compounds as ehmt2 inhibitors |
| DK3582776T3 (da) | 2017-02-14 | 2024-01-08 | Effector Therapeutics Inc | Piperidinsubstituerede mnk-hæmmere og dertil relaterede fremgangsmåder |
| AU2018243749A1 (en) * | 2017-03-31 | 2019-11-21 | Epizyme, Inc. | Methods of using EHMT2 inhibitors |
| US11672800B2 (en) | 2017-04-21 | 2023-06-13 | Epizyme, Inc. | Combination therapies with EHMT2 inhibitors |
| CN111793060B (zh) | 2017-07-14 | 2023-06-06 | 先天肿瘤免疫公司 | Nlrp3调节剂 |
| EP3697419A4 (en) * | 2017-10-17 | 2021-08-18 | Epizyme, Inc. | AMINE SUBSTITUTION HETEROCYCLIC COMPOUNDS USED AS AND DERIVATIVES OF EHMT2 |
| WO2019079540A1 (en) * | 2017-10-18 | 2019-04-25 | Epizyme, Inc. | AMINO-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF EHMT2, SALTS THEREOF, AND METHODS OF SYNTHESIS THEREOF |
| KR20200101332A (ko) * | 2017-10-18 | 2020-08-27 | 에피자임, 인코포레이티드 | 혈액 장애 예방 또는 치료에 있어서의 ehmt2 저해제의 사용 방법 |
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| KR20210102211A (ko) | 2018-10-24 | 2021-08-19 | 이펙터 테라퓨틱스, 인크. | Mnk 억제제의 결정질 형태 |
| WO2020097398A1 (en) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| US12522583B2 (en) | 2018-11-07 | 2026-01-13 | Dana-Farber Cancer Institute, Inc. | Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof |
| WO2020097400A1 (en) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof |
| JP7506080B2 (ja) * | 2019-01-14 | 2024-06-25 | イネイト・テューマー・イミュニティ・インコーポレイテッド | Ｎｌｒｐ３モジュレーター |
| WO2020171646A1 (ko) | 2019-02-22 | 2020-08-27 | 한미약품 주식회사 | Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물 |
| SG11202110591SA (en) * | 2019-03-28 | 2021-10-28 | Epizyme Inc | Quinoline derivatives and their use for the treatment of cancer |
| JP2022538817A (ja) | 2019-06-27 | 2022-09-06 | ハンミ ファーマシューティカル カンパニー リミテッド | Ｆｌｔ３阻害剤および化学療法剤を含む急性骨髄白血病を治療するための薬学的組成物 |
| US11691963B2 (en) | 2020-05-06 | 2023-07-04 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
| CN119954775A (zh) | 2020-12-22 | 2025-05-09 | 益方生物科技(上海)股份有限公司 | 杂芳基化合物及其制备方法和用途 |
| EP4267574B1 (en) | 2020-12-23 | 2025-04-23 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| CA3234693A1 (en) * | 2021-10-15 | 2023-04-20 | Tango Therapeutics, Inc. | Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof |
| CA3234638A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| US12162881B2 (en) | 2021-11-09 | 2024-12-10 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of JAK2 |
| KR20250040981A (ko) * | 2022-07-20 | 2025-03-25 | 주식회사 에스투시바이오 | 헤테로아릴 유도체 화합물 및 이의 용도 |
| CN115974727B (zh) * | 2023-01-17 | 2024-03-12 | 青岛前线生物工程有限公司 | 一种联苯肼酯的合成方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| US6596747B2 (en) * | 1998-10-29 | 2003-07-22 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus and pharmaceutical compositions comprising same |
| JP2002528499A (ja) * | 1998-10-29 | 2002-09-03 | ブリストル−マイヤーズ スクイブ カンパニー | Ｉｍｐｄｈ酵素のインヒビターであるアミノ核誘導化合物 |
| ES2271283T3 (es) * | 2001-07-03 | 2007-04-16 | Vertex Pharmaceuticals Incorporated | Isoxazolil-pirimidinas como inhibidores de las proteinas quinasas src y lck. |
| WO2003040141A1 (en) * | 2001-09-28 | 2003-05-15 | Bayer Pharmaceuticals Corporation | Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders |
| ATE506953T1 (de) | 2003-08-07 | 2011-05-15 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel |
| JP2009501164A (ja) * | 2005-07-15 | 2009-01-15 | ４エスツェー アクチェンゲゼルシャフト | ２−アリールベンゾチアゾール及びその使用 |
| GEP20105074B (en) * | 2005-12-21 | 2010-09-10 | Novartis Ag | Pyrimidinyl aryl urea derivatives being fgf inhibitors |
| TW200902010A (en) * | 2007-01-26 | 2009-01-16 | Smithkline Beecham Corp | Anthranilamide inhibitors of aurora kinase |
| NZ582485A (en) * | 2007-07-17 | 2012-05-25 | Rigel Pharmaceuticals Inc | Cyclic amine substituted pyrimidinediamines as pkc inhibitors |
| JP5328816B2 (ja) * | 2008-02-22 | 2013-10-30 | エフ．ホフマン−ラ ロシュ アーゲー | アミロイドβの調節薬 |
| SG172885A1 (en) * | 2009-01-23 | 2011-08-29 | Rigel Pharmaceuticals Inc | Compositions and methods for inhibition of the jak pathway |
| WO2010129802A1 (en) * | 2009-05-06 | 2010-11-11 | Portola Pharmaceuticals, Inc. | Inhibitors of jak |
| WO2014044025A1 (zh) * | 2012-09-20 | 2014-03-27 | 山东亨利医药科技有限责任公司 | 嘧啶胺衍生物及其制备方法和应用 |
| EP2928891B1 (en) * | 2012-12-04 | 2019-02-20 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
| CA2904610A1 (en) * | 2013-03-14 | 2014-09-25 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
| WO2014152768A1 (en) * | 2013-03-15 | 2014-09-25 | Portola Pharmaceuticals, Inc. | Cyclohexanediamine compounds and methods for their preparation |
| WO2016175264A1 (ja) * | 2015-04-28 | 2016-11-03 | カルナバイオサイエンス株式会社 | 抗マラリア活性を有する新規ヘテロアリール誘導体 |
| WO2017181177A1 (en) * | 2016-04-15 | 2017-10-19 | Epizyme, Inc. | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors |
| CN106083828A (zh) * | 2016-06-30 | 2016-11-09 | 浙江大学 | 含吖丙啶环侧链的芳胺嘧啶衍生物及制备和应用 |
-
2017
- 2017-12-19 TW TW106144660A patent/TWI808067B/zh active
- 2017-12-19 EP EP23186749.0A patent/EP4285906A3/en not_active Withdrawn
- 2017-12-19 ES ES17829454T patent/ES2955132T3/es active Active
- 2017-12-19 MA MA047233A patent/MA47233A/fr unknown
- 2017-12-19 HU HUE17829454A patent/HUE063405T2/hu unknown
- 2017-12-19 EP EP17829454.2A patent/EP3555070B1/en active Active
- 2017-12-19 TW TW112121399A patent/TW202411220A/zh unknown
- 2017-12-19 AU AU2017382830A patent/AU2017382830A1/en not_active Abandoned
- 2017-12-19 BR BR112019012140-4A patent/BR112019012140A2/pt not_active Application Discontinuation
- 2017-12-19 SI SI201731407T patent/SI3555070T1/sl unknown
- 2017-12-19 WO PCT/US2017/067192 patent/WO2018118842A1/en not_active Ceased
- 2017-12-19 US US16/471,151 patent/US20200039998A1/en not_active Abandoned
- 2017-12-19 CA CA3045032A patent/CA3045032A1/en active Pending
- 2017-12-19 DK DK17829454.2T patent/DK3555070T3/da active
- 2017-12-19 CN CN202310013963.4A patent/CN116041346A/zh active Pending
- 2017-12-19 CN CN201780078660.3A patent/CN110088099B/zh active Active
- 2017-12-19 JP JP2019530439A patent/JP2020504715A/ja active Pending
- 2017-12-19 PT PT178294542T patent/PT3555070T/pt unknown
- 2017-12-19 MX MX2019007234A patent/MX2019007234A/es unknown
- 2017-12-19 LT LTEPPCT/US2017/067192T patent/LT3555070T/lt unknown
- 2017-12-19 PL PL17829454.2T patent/PL3555070T3/pl unknown
- 2017-12-19 SG SG10201913464TA patent/SG10201913464TA/en unknown
- 2017-12-19 FI FIEP17829454.2T patent/FI3555070T3/fi active
- 2017-12-19 KR KR1020197020233A patent/KR102693367B1/ko active Active
-
2019
- 2019-06-04 IL IL267090A patent/IL267090A/en unknown
- 2019-06-17 CL CL2019001664A patent/CL2019001664A1/es unknown
- 2019-06-26 CO CONC2019/0006787A patent/CO2019006787A2/es unknown
- 2019-06-27 ZA ZA2019/04234A patent/ZA201904234B/en unknown
-
2020
- 2020-04-29 CL CL2020001133A patent/CL2020001133A1/es unknown
-
2021
- 2021-11-15 US US17/526,058 patent/US20220235065A1/en not_active Abandoned
-
2022
- 2022-04-14 AU AU2022202494A patent/AU2022202494B2/en active Active
- 2022-05-16 JP JP2022080211A patent/JP2022110080A/ja active Pending
-
2024
- 2024-08-01 AU AU2024205290A patent/AU2024205290A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020504715A5 (enExample) | ||
| AU2020201321B2 (en) | Combination therapy including an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| JP2020537645A5 (enExample) | ||
| SI2809657T1 (en) | New therapeutic agents | |
| KR20220049518A (ko) | 피라졸로[3,4-b]피라진 shp2 포스파타제 저해제 | |
| US20030060450A1 (en) | Dosing regimen | |
| US12350265B2 (en) | Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents | |
| JP2019513778A5 (enExample) | ||
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| JP2020531414A5 (enExample) | ||
| JP2019533650A5 (enExample) | ||
| RU2013147823A (ru) | (альфа-замещенные аралкиламино-и гетероарилалкиламино)пиримидинил-и 1, 3, 5-триазинилбензимидазолы, их фармацевтические композиции и их применение в лечении пролиферативных заболеваний | |
| JP2003525244A (ja) | 抗腫瘍性アルキル化剤とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤 | |
| JPWO2021060453A5 (enExample) | ||
| JPWO2020032105A5 (enExample) | ||
| RU2020109775A (ru) | Комплексная терапия | |
| WO2001064218A2 (en) | Farnesyl protein transferase inhibitor combinations | |
| AR045811A1 (es) | 5- arilpirimidinas como agentes ainticancerigenos | |
| CA2663965A1 (en) | Pyrazolopyrimidine derivative and use thereof as an anticancer agent | |
| RU2019104105A (ru) | Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции | |
| WO2021097075A1 (en) | Substituted isoindolonyl 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same | |
| AU2006223000B2 (en) | Methods of treating cancer using PPAR-gamma antagonists | |
| Gutiérrez-Aguirre et al. | Effectiveness of dasatinib in relapsed CNS, Ph+ ALL that is refractory to radiochemotherapy plus imatinib: a case report | |
| HK40078013A (en) | Combination therapy including an mdm2 inhibitor and dasatinib or nilotinib for the treatment of chronic myeloid leukemia | |
| JPWO2021088839A5 (enExample) |